Comparative Pharmacology
Head-to-head clinical analysis: OPANA ER versus STADOL PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OPANA ER versus STADOL PRESERVATIVE FREE.
OPANA ER vs STADOL PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Opana ER (oxymorphone hydrochloride) is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can interact with other opioid receptors at higher doses. The principal therapeutic action is analgesia via activation of mu-opioid receptors in the central nervous system, leading to altered perception and response to pain.
Butorphanol is a synthetic agonist-antagonist opioid analgesic that exerts its effects primarily through binding to kappa-opioid receptors and, to a lesser extent, mu-opioid receptors, producing analgesia and sedation. It also has partial antagonist activity at mu receptors.
Initial: 5 mg orally every 12 hours; titrate by 5-10 mg every 12 hours every 3-7 days; maximum 40 mg every 12 hours.
0.5–2 mg intravenously or intramuscularly every 3–4 hours as needed for pain. Alternatively, 1–2 mg as a single dose, may repeat in 30–60 minutes if needed.
None Documented
None Documented
Terminal elimination half-life: 11.1–13.8 hours; clinically relevant as steady-state achieved in 2–3 days
Terminal elimination half-life is 2.5–3.3 hours in adults; prolonged to 4–6 hours in elderly or hepatic impairment.
Renal (primarily as glucuronide conjugates and unchanged drug): 85-90%; Fecal: <10%
Primarily hepatic metabolism (glucuronidation) to inactive metabolites; renal excretion accounts for <5% unchanged drug. Approximately 70% of dose excreted in urine as metabolites, 20% in feces.
Category C
Category C
Opioid Analgesic
Opioid Analgesic